Nwd1 gene deletion triggers MASH-like pathology in mice
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
Health on MSN10h
How Is Metabolic Dysfunction-Associated Steatohepatitis (MASH) Diagnosed?
Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH) is a disease that occurs when ...
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...
AZoLifeSciences on MSN1d
Study Explores the Physiological Role of Nwd1 Gene in MASH Pathogenesis
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
Medindia3d
Ready to Fight Metabolic Dysfunction-Associated Fatty Liver Disease: Here's How
Ready to save your liver? Transcription factors are paving the way for metabolic dysfunction-associated fatty liver disease ...
News-Medical.Net on MSN3d
Study reveals the role of transcription factors as therapeutic gateways in MAFLD
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
AlphaGalileo4d
New Avenues for Treating Metabolic Dysfunction-Associated Fatty Liver Disease
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...
Everyday Health2d
Consumer's Guide to THR-Beta Agonists for MASH
THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.
Sagimet Biosciences Inc.: Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation ...
News Medical on MSN3d
Gene Deletion Sparks MASH Pathology in Mice Breakthrough
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
European Medical Journal3d
Breaking Down Liver Disease: Interview with Scott Friedman
The number one unmet need is that we don't have a good handle on who's at risk, because patients generally don't have too ...